The use and therapeutic drug monitoring of teicoplanin in the UK

Slides:

Advertisements

Similar presentations

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Advertisements

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

Gut bacterial microbiota and obesity

I.J. Schalk Clinical Microbiology and Infection

Approach to diagnosis of infective endocarditis

Varicella vaccination: a laboured take-off

Association of vancomycin serum concentrations with efficacy in patients with MRSA infections: a systematic review and meta-analysis T. Steinmetz, N.

The efficacy and safety of daptomycin: first in a new class of antibiotics for Gram- positive bacteria M.J. Rybak Clinical Microbiology and Infection

Migrant health—a cause for concern?

C.-S. Lee, J.-H. Lee Clinical Microbiology and Infection

J.-P. Van geertruyden Clinical Microbiology and Infection

Virological tools to diagnose and monitor hepatitis C virus infection

R. Cantón Clinical Microbiology and Infection

Genital Chlamydia trachomatis infections

Antimicrobial drug use and infection control practices associated with the prevalence of methicillin-resistant Staphylococcus aureus in European hospitals

A. Domínguez-Gil Hurlé, A. Sánchez Navarro, M.J. García Sánchez

Louis Pasteur, from crystals of life to vaccination

How to evaluate and predict the ecologic impact of antibiotics: the pharmaceutical industry view from research and development R. Bax Clinical Microbiology.

J.-P. Stahl Clinical Microbiology and Infection

Use of surveillance cultures and enteral vancomycin to control methicillin-resistant Staphylococcus aureus in a paediatric intensive care unit K. Thorburn,

Surveillance of Legionnaires’ disease in Austria

How to evaluate and predict the epidemiologic impact of antibiotic use in humans: the pharmacoepidemiologic approach D. Guillemot Clinical Microbiology.

Vector control: a cornerstone in the malaria elimination campaign

J.P. Donnelly, B.E. De Pauw Clinical Microbiology and Infection

Training for the infectious diseases speciality in Norway

Low prevalence of methicillin-resistant Staphylococcus aureus with reduced susceptibility to glycopeptides in Belgian hospitals C. Nonhoff, O. Denis,

B. Gordts Clinical Microbiology and Infection

CMI editorial report 2011 Clinical Microbiology and Infection

The clinical efficacy of triclosan/copolymer and other common therapeutic approaches to periodontal health R.M. Davies Clinical Microbiology and Infection

Bacterial resistance—the clinical challenge

Clinical and microbiological characteristics of Nocardiosis including those caused by emerging Nocardia species in Taiwan, 1998–2008 C.-K. Tan, C.-C.

Comparison of clinical and environmental isolates of Legionella pneumophila obtained in the UK over 19 years T.G. Harrison, N. Doshi, N.K. Fry, C.A.

Elements of design: the knowledge on which we build

Levofloxacin in the treatment of ventilator-associated pneumonia

Acute schistosomiasis, a diagnostic and therapeutic challenge

Metagenomics and probiotics

Previously unknown species of Aspergillus

Laboratory diagnosis of Clostridium difficile disease

W.A. Craig Clinical Microbiology and Infection

Voriconazole concentrations and outcome of invasive fungal infections

The practice of travel medicine in Europe

T.M. File Clinical Microbiology and Infection

Antibacterial drug discovery in the 21st century

Abstracts cont. Clinical Microbiology and Infection

Pandemic lineages of extraintestinal pathogenic Escherichia coli

P.M. Hawkey Clinical Microbiology and Infection

Current experience in treating invasive zygomycosis with posaconazole

Antimicrobial drug development – the past, the present, and the future

H. Leblebicioglu, C. Eroglu Clinical Microbiology and Infection

Sequential time to positivity of blood cultures can be a predictor of prognosis of patients with persistent Staphylococcus aureus bacteraemia M.-S. Hsu,

Statin use and clinical outcomes among pneumonia patients

Clinical Microbiology and Infection

Listeriosis: a resurgent foodborne infection

Overview of cefixime use in community-acquired infections

K. Kaier, N.T. Mutters, U. Frank Clinical Microbiology and Infection

The atypical pneumonias: clinical diagnosis and importance

Abstracts Clinical Microbiology and Infection

Modelling during an emergency: the 2009 H1N1 influenza pandemic

New oral cephalosporins in pediatric community-acquired infections

A. Manzur, F. Gudiol Clinical Microbiology and Infection

O. Megged, A.M. Yinnon, D. Raveh, B. Rudensky, Y. Schlesinger

B.A. Cunha Clinical Microbiology and Infection

J.L. Balcázar Clinical Microbiology and Infection

G.C. Schito Clinical Microbiology and Infection

Impact of antibiotic restrictions: the patient's perspective

Comparative study of pediculicidal effect of medical plants

J. Segreti Clinical Microbiology and Infection

Abstracts Clinical Microbiology and Infection

CMI readers' survey Clinical Microbiology and Infection

The future of diagnostic bacteriology

Presentation transcript:

The use and therapeutic drug monitoring of teicoplanin in the UK E.S.R. Darley Clinical Microbiology and Infection Volume 10, Issue 1, Pages 62-69 (January 2004) DOI: 10.1111/j.1469-0691.2004.00747.x Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 1 Recommended daily teicoplanin dosage (mg/kg) for MRSA cellulitis. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide, once-daily. Clinical Microbiology and Infection 2004 10, 62-69DOI: (10.1111/j.1469-0691.2004.00747.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 2 Desired pre-dose teicoplanin concentrations for MRSA cellulitis according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide. Clinical Microbiology and Infection 2004 10, 62-69DOI: (10.1111/j.1469-0691.2004.00747.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 3 Desired pre-dose teicoplanin concentrations for MRSA osteomyelitis according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide. Clinical Microbiology and Infection 2004 10, 62-69DOI: (10.1111/j.1469-0691.2004.00747.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions

Fig. 4 Desired pre-dose teicoplanin concentrations for MRSA bacteraemia according to preferred glycopeptide. T users, V users: microbiologists using, respectively, teicoplanin or vancomycin as their first-choice glycopeptide. Clinical Microbiology and Infection 2004 10, 62-69DOI: (10.1111/j.1469-0691.2004.00747.x) Copyright © 2004 European Society of Clinical Infectious Diseases Terms and Conditions